^
Association details:
Biomarker:MYCL overexpression
Cancer:Multiple Myeloma
Drug:JQ-1 (BET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL

Excerpt:
Our aim was to analyse the antimyeloma activity of BET inhibitors on U266 cells. Two BET inhibitors, I-BET151 and JQ1, were tested. BET inhibitors decreased the cell proliferation in U266 cells with overexpression of MYCL less than those without overexpression of MYCL.
DOI:
10.1097/CAD.0000000000000389